Want to see AU:NOX full AI Analyst Report?
NOX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.99%)
At close: 4:00 PM EST
AU$0.09
>-AU$0.01(-8.99%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.14
Previous CloseN/A
Volume154.85K
Average Volume (3M)123.50K
Market Cap
AU$29.34M
Enterprise ValueAU$28.12M
Total Cash (Recent Filing)AU$91.40K
Total Debt (Recent Filing)AU$4.25M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology-focused R&DA clear strategic focus on oncology R&D aligns the company with a structurally growing therapeutic area and high unmet medical need. Persistent demand for improved cancer treatments supports long-term commercial opportunity if clinical programs advance successfully.
Revenue Uptick In 2025A ~20% revenue recovery in 2025 indicates the business can generate improving top-line momentum after prior declines. Sustained revenue growth reduces reliance solely on financing and, if continued, supports longer-term investment in R&D and commercial development.
Improving Free Cash Flow TrendAn improving free cash flow trend, even if still negative, signals progress toward better cash efficiency and operational control. A persistent improvement trajectory can materially extend runway and lower near-term external financing needs.
Bears Say
Weakened Balance Sheet And High LeverageDebt roughly 3.6x equity and falling shareholder equity materially reduce capital flexibility and increase solvency risk. High leverage in a development-stage biotech elevates the probability of dilutive financing or constrained strategic options over the coming months.
Persistent Cash BurnConsistent negative operating and free cash flows mean the company depends on external funding to sustain operations. This structural cash shortfall increases financing risk, potential dilution, and vulnerability to tighter capital markets or sponsor fatigue.
Ongoing Large Net Losses And Negative MarginsNegative gross profit and persistent large losses indicate the core business is not yet economically sustainable. Until clinical or commercial milestones translate into durable positive margins, the company faces continuous execution and funding risk.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.04 and its highest was AU$0.14 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$29.34M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 48 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NOX Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
2509.60%
Trailing 12-Months
Asset Growth
-13.13%
Trailing 12-Months
Company Description
Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―